Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been making waves in the healthcare sector with its groundbreaking treatments for ...

Target’s rollback on diversity, equity and inclusion initiatives is raising questions about the retail giant’s philanthropic ...

RICHMOND, VA - Indivior PLC (LON:INDV), a pharmaceutical company specializing in treatments for substance use disorders, ...

Tracey Allen Franks, age 59, of Indianapolis, IN, was born on Nov. 26, 1965, in Seymour, IN, to parents Bruce and Virginia ...

30,134 people played the daily Crossword recently. Can you solve it faster than others?30,134 people played the daily Crossword recently. Can you solve it faster than others?

Deep-pocketed investors have adopted a bearish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

The FDA previously rejected an Eli Lilly–partnered drug that had been licensed from ... “No matter who comes into the administration, I think it’s a matter of pride to say that this is an American ...

Approval was based on results of the VIVID-1 study, which found that Omvoh demonstrated significant clinical remission and endoscopic response rates in patients with Crohn disease. The FDA has ...

Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn's disease, an inflammatory bowel disease that causes chronic abdominal pain.

Eli Lilly (LLY) announced that the FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.S. for two types of ...